Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Current Nutrition Reports
Published in: Current Nutrition Reports 2/2020

01-06-2020 | Nicotinic Acid | Nutrition and Aging (Y Gu, Section Editor)

The Role of Nutrition in Individualized Alzheimer’s Risk Reduction

Authors: Yasmin Amini, Nabeel Saif, Christine Greer, Hollie Hristov, Richard Isaacson

Published in: Current Nutrition Reports | Issue 2/2020

Login to get access

Abstract

Purpose of Review

Decades of research suggests nutritional interventions can be an effective tool for reducing risk of Alzheimer’s disease (AD), especially as part of an individualized clinical management plan. This review aims to emphasize new findings examining how specific dietary changes may delay or possibly prevent AD onset, and highlight how interventions can be adopted in clinical practice based on emerging principles of precision medicine.

Recent Findings

Specific dietary patterns and varied nutrient combinations can have a protective effect on brain health, promote cognitive function, and mediate the comorbidity of chronic conditions associated with increased AD risk.

Summary

Individuals at risk for AD may see a greater impact of evidence-based dietary changes when initiated earlier in the AD spectrum. Depending on individual clinical profiles, incorporation of nutrition strategies is an essential component of an AD risk reduction plan in clinical practice.
Literature
1.
Association As. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 2019;15(3):321–87.CrossRef
2.
Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer’s disease in the United States. Alzheimers Dement. 2018;14(2):121–9.PubMedCrossRef
3.
Livingston G, Sommerlad A, Orgeta V, Costafreda SG, Huntley J, Ames D, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673–734.PubMedCrossRef
4.
Schelke MW, Attia P, Palenchar DJ, Kaplan B, Mureb M, Ganzer CA, et al. Mechanisms of risk reduction in the clinical practice of Alzheimer’s disease prevention. Front Aging Neurosci. 2018;10:96.PubMedPubMedCentralCrossRef
5.
Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788–94.PubMedCrossRef
6.
Brayne C, Miller B. Dementia and aging populations—a global priority for contextualized research and health policy. Public Library of Science; 2017.
7.
Hodes JF, Oakley CI, O’Keefe JH, Lu P, Galvin JE, Saif N, et al. Alzheimer’s “Prevention” vs.“Risk Reduction”: transcending semantics for clinical practice. Front Neurol. 2018;9.
8.
•• Isaacson RS, Ganzer CA, Hristov H, Hackett K, Caesar E, Cohen R, et al. The clinical practice of risk reduction for Alzheimer’s disease: a precision medicine approach. Alzheimers Dement. 2018;14(12):1663–73. Importance: This study describes a novel clinical methodology used to assess risk and inform therapeutic interventions for individual patients seeking treatment for AD prevention. Preliminary results provided in the paper suggest risk reduction is possible, with measurable improvements of cognition and biomarkers of AD risk. The discussion also evaluates the effectiveness of personalized clinical management plans and feasibility of future research in the field of individualized AD prevention.PubMedPubMedCentralCrossRef
9.
• Schelke MW, Hackett K, Chen JL, Shih C, Shum J, Montgomery ME, et al. Nutritional interventions for Alzheimer’s prevention: a clinical precision medicine approach. Ann N Y Acad Sci. 2016;1367(1):50. Importance: This analysis of existing nutritional modalities provides background that can inform preventive AD dietary interventions. It also reports preliminary results from the first US Alzheimer’s Prevention Clinic, highlighting the unmet need for individualized precision medicine in clinical AD care.PubMedPubMedCentralCrossRef
10.
Pistollato F, Iglesias RC, Ruiz R, Aparicio S, Crespo J, Lopez LD, et al. Nutritional patterns associated with the maintenance of neurocognitive functions and the risk of dementia and Alzheimer’s disease: a focus on human studies. Pharmacol Res. 2018;131:32–43.PubMedCrossRef
11.
Shah R. The role of nutrition and diet in Alzheimer disease: a systematic review. J Am Med Dir Assoc. 2013;14(6):398–402.PubMedCrossRef
12.
Bloom GS, Lazo JS, Norambuena A. Reduced brain insulin signaling: a seminal process in Alzheimer’s disease pathogenesis. Neuropharmacology. 2018;136:192–5.PubMedCrossRef
13.
14.
Seifan A, Isaacson R. The Alzheimer’s prevention clinic at Weill Cornell Medical College/New York-Presbyterian Hospital: risk stratification and personalized early intervention. J Prev Alzheimers Dis. 2015;2(4):254–66.PubMedPubMedCentral
15.
Frith E, Shivappa N, Mann JR, Hébert JR, Wirth MD, Loprinzi PD. Dietary inflammatory index and memory function: population-based national sample of elderly Americans. Br J Nutr. 2018;119(5):552–8.PubMedPubMedCentralCrossRef
16.
Anastasiou CA, Yannakoulia M, Kosmidis MH, Dardiotis E, Hadjigeorgiou GM, Sakka P, et al. Mediterranean diet and cognitive health: initial results from the Hellenic Longitudinal Investigation of Ageing and Diet. PLoS One. 2017;12(8):e0182048.PubMedPubMedCentralCrossRef
17.
• McGrattan AM, McGuinness B, McKinley MC, Kee F, Passmore P, Woodside JV, et al. Diet and inflammation in cognitive ageing and Alzheimer’s disease. Curr Nutr Rep. 2019;8(2):53–65. This review provides evidence on the impact of healthy dietary patterns on cognitive functioning. The authors specifically highlight findings surrounding anti-inflammatory diets (such as MIND and DASH) and the mechanisms by which they mitigate neuro-inflammation via indirect integumentary and circulatory pathways.PubMedPubMedCentralCrossRef
18.
Lau FC, Shukitt-Hale B, Joseph JA. Nutritional intervention in brain aging. Inflammation in the pathogenesis of chronic diseases: Springer; 2007. p. 299–318.
19.
20.
Agosti P, Custodero C, Schilardi A, Valiani V, D’Introno A, Lozupone M, et al. Nutritional interventions in patients with Alzheimer’s disease and other late-life cognitive disorders. J Gerontol Geriatr. 2018;66(2):101–18.
21.
Holland TM, Agarwal P, Wang Y, Leurgans SE, Bennett DA, Booth SL, et al. Dietary flavonols and risk of Alzheimer dementia. Neurology. 2020.
22.
23.
Khan H, Ullah H, Aschner M, Cheang WS, Akkol EK. Neuroprotective effects of quercetin in Alzheimer’s disease. Biomolecules. 2020;10(1):59.CrossRef
24.
Mastroiacovo D, Kwik-Uribe C, Grassi D, Necozione S, Raffaele A, Pistacchio L, et al. Cocoa flavanol consumption improves cognitive function, blood pressure control, and metabolic profile in elderly subjects: the Cocoa, Cognition, and Aging (CoCoA) study—a randomized controlled trial. Am J Clin Nutr. 2015;101(3):538–48.PubMedCrossRef
25.
Dolan C, Glynn R, Griffin S, Conroy C, Loftus C, Wiehe P, et al. Brain complications of diabetes mellitus: a cross-sectional study of awareness among individuals with diabetes and the general population in Ireland. Diabet Med. 2018;35(7):871–9.PubMedCrossRef
26.
Lee HJ, Seo HI, Cha HY, Yang YJ, Kwon SH, Yang SJ. Diabetes and Alzheimer’s disease: mechanisms and nutritional aspects. Clin Nutr Res. 2018;7(4):229–40.PubMedPubMedCentralCrossRef
27.
28.
Bosco D, Fava A, Plastino M, Montalcini T, Pujia A. Possible implications of insulin resistance and glucose metabolism in Alzheimer’s disease pathogenesis. J Cell Mol Med. 2011;15(9):1807–21.PubMedPubMedCentralCrossRef
29.
Ashfaq M, Talreja N, Chuahan D, Srituravanich W. Carbon nanostructure-based materials: a novel tool for detection of Alzheimer’s disease. Biological, Diagnostic and Therapeutic Advances in Alzheimer’s Disease: Springer; 2019. p. 71–89.
30.
Taylor MK, Sullivan DK, Swerdlow RH, Vidoni ED, Morris JK, Mahnken JD, et al. A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults. Am J Clin Nutr. 2017;106(6):1463–70.PubMedPubMedCentralCrossRef
31.
Johnson ML, Distelmaier K, Lanza IR, Irving BA, Robinson MM, Konopka AR, et al. Mechanism by which caloric restriction improves insulin sensitivity in sedentary obese adults. Diabetes. 2016;65(1):74–84.PubMed
32.
Aksungar FB, Sarikaya M, Coskun A, Serteser M, Unsal I. Comparison of intermittent fasting versus caloric restriction in obese subjects: a two year follow-up. J Nutr Health Aging. 2017;21(6):681–5.PubMedCrossRef
33.
Corley B, Carroll R, Hall R, Weatherall M, Parry-Strong A, Krebs J. Intermittent fasting in type 2 diabetes mellitus and the risk of hypoglycaemia: a randomized controlled trial. Diabet Med. 2018;35(5):588–94.PubMedCrossRef
34.
35.
Craft S, Claxton A, Baker LD, Hanson AJ, Cholerton B, Trittschuh EH, et al. Effects of regular and long-acting insulin on cognition and Alzheimer’s disease biomarkers: a pilot clinical trial. J Alzheimers Dis. 2017;57(4):1325–34.PubMedPubMedCentralCrossRef
36.
Chapman CD, Schiöth HB, Grillo CA, Benedict C. Intranasal insulin in Alzheimer’s disease: food for thought. Neuropharmacology. 2018;136:196–201.PubMedCrossRef
37.
Rojas-Gutierrez E, Muñoz-Arenas G, Treviño S, Espinosa B, Chavez R, Rojas K, et al. Alzheimer’s disease and metabolic syndrome: a link from oxidative stress and inflammation to neurodegeneration. Synapse. 2017;71(10):e21990.PubMedCrossRef
38.
de Lima Oliveira BC, Bellozi PMQ, Reis HJ, de Oliveira ACP. Inflammation as a possible link between dyslipidemia and Alzheimer’s disease. Neuroscience. 2018;376:127–41.CrossRef
39.
Jonsson T, Stefansson H, Steinberg S, Jonsdottir I, Jonsson PV, Snaedal J, et al. Variant of TREM2 associated with the risk of Alzheimer’s disease. N Engl J Med. 2013;368(2):107–16.PubMedCrossRef
40.
Loera-Valencia R, Goikolea J, Parrado-Fernandez C, Merino-Serrais P, Maioli S. Alterations in cholesterol metabolism as a risk factor for developing Alzheimer´ s disease: potential novel targets for treatment. J Steroid Biochem Mol Biol. 2019.
41.
Celik E, Sanlier N. Effects of nutrient and bioactive food components on Alzheimer’s disease and epigenetic. Crit Rev Food Sci Nutr. 2019;59(1):102–13.PubMedCrossRef
42.
Qin B, Xun P, Jacobs DR Jr, Zhu N, Daviglus ML, Reis JP, et al. Intake of niacin, folate, vitamin B-6, and vitamin B-12 through young adulthood and cognitive function in midlife: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Am J Clin Nutr. 2017;106(4):1032–40.PubMedPubMedCentralCrossRef
43.
Morris MC, Evans DA, Bienias JL, Scherr PA, Tangney CC, Hebert LE, et al. Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J Neurol Neurosurg Psychiatry. 2004;75(8):1093–9.PubMedPubMedCentralCrossRef
44.
Mielgo-Ayuso J, Aparicio-Ugarriza R, Olza J, Aranceta-Bartrina J, Gil Á, Ortega RM, et al. Dietary intake and food sources of niacin, riboflavin, thiamin and vitamin B6 in a representative sample of the Spanish population. The ANIBES Study. Nutrients. 2018;10(7):846.PubMedCentralCrossRef
45.
Moloney M. The role of omega-3 fatty acids in the prevention of Alzheimer’s disease in the early stages of disease presentation. J Aust Tradit Med Soc. 2019;25(2):90.
46.
Nolan JM, Mulcahy R, Power R, Moran R, Howard AN. Nutritional intervention to prevent Alzheimer’s disease: potential benefits of xanthophyll carotenoids and omega-3 fatty acids combined. J Alzheimers Dis. 2018;64(2):367–78.PubMedCrossRef
47.
Power MC, Rawlings A, Sharrett AR, Bandeen-Roche K, Coresh J, Ballantyne CM, et al. Association of midlife lipids with 20-year cognitive change: a cohort study. Alzheimers Dement. 2018;14(2):167–77.PubMedCrossRef
48.
Mecocci P, Boccardi V, Cecchetti R, Bastiani P, Scamosci M, Ruggiero C, et al. A long journey into aging, brain aging, and Alzheimer’s disease following the oxidative stress tracks. J Alzheimers Dis. 2018;62(3):1319–35.PubMedPubMedCentralCrossRef
49.
Ballaz SJ, Rebec GV. Neurobiology of vitamin C: expanding the focus from antioxidant to endogenous neuromodulator. Pharmacol Res 2019:104321.
50.
Yassine HN, Braskie MN, Mack WJ, Castor KJ, Fonteh AN, Schneider LS, et al. Association of docosahexaenoic acid supplementation with Alzheimer disease stage in apolipoprotein E ε4 carriers: a review. JAMA Neurol. 2017;74(3):339–47.PubMedPubMedCentralCrossRef
51.
Kryscio RJ, Abner EL, Caban-Holt A, Lovell M, Goodman P, Darke AK, et al. Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (PREADViSE). JAMA Neurol. 2017;74(5):567–73.PubMedPubMedCentralCrossRef
52.
Yusufov M, Weyandt LL, Piryatinsky I. Alzheimer’s disease and diet: a systematic review. Int J Neurosci. 2017;127(2):161–75.PubMedCrossRef
53.
Smith AD, Smith SM, De Jager CA, Whitbread P, Johnston C, Agacinski G, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5(9).
54.
Velazquez R, Ferreira E, Winslow W, Dave N, Piras IS, Naymik M, et al. Maternal choline supplementation ameliorates Alzheimer’s disease pathology by reducing brain homocysteine levels across multiple generations. Mol Psychiatry 2019:1–10.
55.
Li JG, Chu J, Barrero C, Merali S, Praticò D. Homocysteine exacerbates β-amyloid pathology, tau pathology, and cognitive deficit in a mouse model of Alzheimer disease with plaques and tangles. Ann Neurol. 2014;75(6):851–63.PubMedPubMedCentralCrossRef
56.
Maddock J, Cavadino A, Power C, Hyppönen E. 25-hydroxyvitamin D, APOE ɛ4 genotype and cognitive function: findings from the 1958 British birth cohort. Eur J Clin Nutr. 2015;69(4):505–8.PubMedCrossRef
57.
58.
Isaacson RS, Hristov H, Saif N, Hackett K, Hendrix S, Melendez J, et al. Individualized clinical management of patients at risk for Alzheimer’s dementia. Alzheimers Dement. 2019;15(12):1588–602.PubMedPubMedCentralCrossRef
59.
Frazier HN, Ghoweri AO, Anderson KL, Lin R-L, Porter NM, Thibault O. Broadening the definition of brain insulin resistance in aging and Alzheimer’s disease. Exp Neurol. 2019;313:79–87.PubMedCrossRef
60.
Hill E, Goodwill AM, Gorelik A, Szoeke C. Diet and biomarkers of Alzheimer’s disease: a systematic review and meta-analysis. Neurobiol Aging. 2019;76:45–52.PubMedCrossRef
61.
Walters M, Hackett K, Caesar E, Isaacson R, Mosconi L. Role of nutrition to promote healthy brain aging and reduce risk of Alzheimer’s disease. Curr Nutr Rep. 2017;6(2):63–71.CrossRef
62.
Isaacson R, Haynes N, Seifan A, Larsen D, Christiansen S, Berger J, et al. Alzheimer’s prevention education: if we build it, will they come? www. AlzU. org. J Prev Alzheimers Dis. 2014;1(2):91.PubMedPubMedCentral
Metadata
Title
The Role of Nutrition in Individualized Alzheimer’s Risk Reduction
Authors
Yasmin Amini
Nabeel Saif
Christine Greer
Hollie Hristov
Richard Isaacson
Publication date
01-06-2020
Publisher
Springer US
Published in
Current Nutrition Reports / Issue 2/2020
Electronic ISSN: 2161-3311
DOI
https://doi.org/10.1007/s13668-020-00311-7

Other articles of this Issue 2/2020

Current Nutrition Reports 2/2020 Go to the issue

Nutrition and Aging (Y Gu, Section Editor)

Healthy Lifestyle and Cognition: Interaction between Diet and Physical Activity

Nutrition and the Brain (J Nasser, Section Editor)

The Effect of Food Composition and Behavior on Neurobiological Response to Food: a Review of Recent Research

Maternal and Childhood Nutrition (AC Wood, Section Editor)

Why Pregnancy Weight Gain Guidelines Need to Differ for Multiple Versus Single Pregnancies

Maternal and Childhood Nutrition (AC Wood, Section Editor)

The Pediatric Obesity Encounter: Literature and Resources to Help with 4 Common Issues

Maternal and Childhood Nutrition (AC Wood, Section Editor)

Food Insecurity and Psychological Distress: a Review of the Recent Literature

Maternal and Childhood Nutrition (AC Wood, Section Editor)

Metabolites Linking the Gut Microbiome with Risk for Type 2 Diabetes

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits